Does the Glucagon-like Peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol intake in patients with Alcohol Use Disorder and comorbid obesity?

To join this study, you need to be an adult, at least 18 years old. Both men and women can take part. The study is specifically looking for people who have been diagnosed with alcohol use disorder and also have obesity. This means you would need to meet certain medical criteria for both conditions.

There will be specific health checks and other requirements that the study doctors will go over with you. These are in place to make sure the study is safe for you and that the results are as clear as possible. Things like other existing health conditions or medicines you are taking might affect whether you can join.

If you decide to participate, you would be randomly assigned to one of two groups: either receiving the study medicine, semaglutide, or a 'dummy' injection called saline. You wouldn't know which one you are getting. Both are given as an injection under the skin using a pre-filled pen. The treatment period would last for 26 weeks, which is about six months.

Throughout the study, you would attend regular visits to the clinic. During these visits, the research team would assess your alcohol consumption using specific methods, monitor your general health, take blood samples, and perhaps conduct other tests like brain scans. They will be looking at how your drinking patterns change, how you feel, and any effects the treatment might have on your body. After the 26-week treatment, there might be a follow-up period to see how you are doing.